A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants
with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this
study will be to investigate the recommended dose of R-DXd that can be given safely to
participants, assess the side effects of R-DXd, and evaluate the effectiveness of R-DXd.
with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this
study will be to investigate the recommended dose of R-DXd that can be given safely to
participants, assess the side effects of R-DXd, and evaluate the effectiveness of R-DXd.
Kidney (Renal Cell),
Ovarian,
Phase I
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
DS-6000a
Rini, Brian
National
Vanderbilt University
07-19-2021
Eligibility
18 Years
BOTH
NO
Inclusion Criteria:
Written informed consent
At least 18 years of age
Eastern Cooperative Oncology Group Performance Status score of 0 or 1
Availability of archived tumor tissue samples
Has a left ventricular ejection fraction (LVEF) 50% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before start of study treatment
Has adequate organ function within 7 days before the start of study treatment
Has an adequate treatment washout period prior to start of study treatment
Male participants with female partners of childbearing potential and female participants of child-bearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4 months (for males) and for at least 7 months (for females) after the last dose of study drug.
Exclusion Criteria:
Has had prior treatment with other CDH6-targeted agents
Has had prior treatment with an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, DS-1062a, DS-7300a)
Has history or current presence of CNS metastases except for participants who have completed radiotherapy or surgery 2 weeks before the start of study treatment and have no evidence of disease progression in the CNS and no requirement for chronic corticosteroid therapy within 2 weeks before the start of study treatment
Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for 3 years)
Has a history of myocardial infarction or unstable angina within 6 months before start of study treatment
Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a serious cardiac arrhythmia requiring treatment
Lung-specific intercurrent clinically significant illnesses
Has an uncontrolled infection requiring systemic therapy
Written informed consent
At least 18 years of age
Eastern Cooperative Oncology Group Performance Status score of 0 or 1
Availability of archived tumor tissue samples
Has a left ventricular ejection fraction (LVEF) 50% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before start of study treatment
Has adequate organ function within 7 days before the start of study treatment
Has an adequate treatment washout period prior to start of study treatment
Male participants with female partners of childbearing potential and female participants of child-bearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4 months (for males) and for at least 7 months (for females) after the last dose of study drug.
Exclusion Criteria:
Has had prior treatment with other CDH6-targeted agents
Has had prior treatment with an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, DS-1062a, DS-7300a)
Has history or current presence of CNS metastases except for participants who have completed radiotherapy or surgery 2 weeks before the start of study treatment and have no evidence of disease progression in the CNS and no requirement for chronic corticosteroid therapy within 2 weeks before the start of study treatment
Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for 3 years)
Has a history of myocardial infarction or unstable angina within 6 months before start of study treatment
Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a serious cardiac arrhythmia requiring treatment
Lung-specific intercurrent clinically significant illnesses
Has an uncontrolled infection requiring systemic therapy
